Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE

• Published in: Cardiovascular drugs and therapy 2022-02, Vol.36 (1), p.69-73
• Main Authors: Xiao, Yichao, Tang, Liang, Liu, Qiming, Hu, Xinqun, Fang, Zhenfei, Zhou, Shenghua
• Format: Article
• Language: English
• Subjects: Active control; Acute Coronary Syndrome - drug therapy; Acute coronary syndromes; Anticoagulants; Anticoagulants - administration & dosage; Anticoagulants - adverse effects; Asian People; Aspirin; Bleeding; Cardiology; Cerebral infarction; Clopidogrel; Dose-Response Relationship, Drug; Enoxaparin - administration & dosage; Enoxaparin - adverse effects; Heart; Hemorrhage - chemically induced; Hemostasis; Hemostatics; Hospitalization; Humans; Ischemia; Medicine; Medicine & Public Health; Multicenter Studies as Topic; Myocardial infarction; Original Article; Patients; Platelet Aggregation Inhibitors - administration & dosage; Prospective Studies; Randomization; Randomized Controlled Trials as Topic; Reperfusion; Rivaroxaban - administration & dosage; Rivaroxaban - adverse effects; Safety; Therapy; Thromboembolism; Thrombosis
• ISSN: 0920-3206; 1573-7241
• DOI: 10.1007/s10557-020-07076-9

Background Acute coronary syndrome (ACS) is a serious and life-threatening condition. Anticoagulation during the acute phase of ACS is effective in reducing ischemic events. The most widely used parenteral anticoagulation agent in ACS patients is enoxaparin. Rivaroxaban is a novel oral anticoagulant with potent anti-Xa activity, which might be an attractive alternative drug to enoxaparin. In fact, rivaroxaban was consistently shown to be non-inferior to enoxaparin therapy in terms of reduction of recurrent venous thromboembolism events. Objective This prospective, randomized, open-label, active-controlled, multicenter study is designed to compare the safety and efficacy of rivaroxaban versus enoxaparin in patients with ACS, who missed the primary reperfusion therapy window and before selective revascularization. Methods and Results Up to 2055 participants receiving background treatment of aspirin plus clopidogrel or ticagrelor will be randomly assigned to either oral rivaroxaban 2.5 mg twice daily or rivaroxaban 5 mg twice daily or subcutaneous enoxaparin 1 mg/kg twice daily until hospital discharge for a maximum of 8 days or 12 h before revascularization therapy. The primary safety endpoint is the International Society on Thrombosis and Hemostasis definition of bleeding events [minor, clinically relevant non-major and major bleeding]. The primary efficacy endpoint is a composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction, re-revascularization or stroke, and major bleeding events. Secondary endpoints include cardiac-related rehospitalization and all-cause death. Patients will be followed for 12 months after randomization. Conclusions The H-REPLACE trial offers an opportunity to assess clinical outcomes of rivaroxaban versus enoxaparin during the acute phase of ACS and may provide an alternative anticoagulation strategy for ACS patients, who missed the primary reperfusion therapy window and before selective revascularization. Trial Registration ClinicalTrials.gov; NCT03363035.